Breast cancer Trials in Oviedo, Spain
Conditions / Breast cancer / Oviedo, Spain
Breast cancer has been the subject of sustained clinical investigation across multiple research sites.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01610284 | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor | COMPLETED | PHASE3 |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | COMPLETED | PHASE2 |
| NCT05592483 | An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer | TERMINATED | — |
| NCT00099437 | Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01565083 | A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer | COMPLETED | PHASE2 |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | COMPLETED | PHASE3 |
| NCT01095003 | Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer | COMPLETED | PHASE3 |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05038735 | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | ACTIVE_NOT_RECRUITING | PHASE3 |